To the Editor: The Emerging Risk Factors Collaboration (ERFC) reported on the addition of lipid-related markers to total cholesterol and high-density lipoprotein cholesterol (HDL-C) in the prediction of cardiovascular disease. We attempted to replicate the findings of eTable 1, which summarized the 26 studies that compared apolipoprotein B with the cholesterol markers. Many discrepancies with the primary publications were found. First, 4 eligible studies, including the Framingham Offspring Study, were not included. Second, 5 studies did not meet the entry criteria, which included approved definitions and recording of both fatal and nonfatal cardiovascular events. The Whitehall I study recorded only fatal ischemic heart disease and so should not have been eligible. Yet strokes were listed in eTable 1 even though they were not a protocol outcome. Third, in 19 of the 26 studies, the number of participants differed substantially between eTable 1 and the primary publication. In 14 studies, there were fewer participants whereas in 5 studies, there were more participants. For example, the ERFC study listed 1293 patients for the Quebec Cardiovascular Study vs the actual tally of 2072. The ERFC study listed 23 175 for the Women’s Health Study vs 15 632 in the primary report. Fourth, the values for apolipoprotein B in 4 study reports differed substantially from those given by the ERFC and neither the methods to measure apolipoprotein B nor the results were given in 4 other studies. Furthermore, in at least 2 studies, apolipoprotein B was measured many years after collection with no documentation of adequate sample preservation. Fifth, the methods and results of 11 studies have not been recorded in the public domain. We assume there are reasonable explanations for the discrepancies but, even so, the ERFC publication is difficult to reconcile with the primary material. Given the apparent deficiencies and discrepancies, the validity of the ERFC findings and their recommendations need to be reexamined. Additional details are available from the author on request.
[1]
K. Castro,et al.
Is it time to replace the tuberculin skin test with a blood test?
,
2012,
JAMA.
[2]
J. Gallacher,et al.
Lipid-related markers and cardiovascular disease prediction.
,
2012,
JAMA.
[3]
C. Furberg,et al.
A Meta-Analysis of Low-Density Lipoprotein Cholesterol, Non-High-Density Lipoprotein Cholesterol, and Apolipoprotein B as Markers of Cardiovascular Risk
,
2011,
Circulation. Cardiovascular quality and outcomes.
[4]
J. Kaldor,et al.
Updated guidelines for using Interferon Gamma Release Assays to detect Mycobacterium tuberculosis infection - United States, 2010.
,
2010,
MMWR. Recommendations and reports : Morbidity and mortality weekly report. Recommendations and reports.
[5]
Sarah Parish,et al.
The joint effects of apolipoprotein B, apolipoprotein A1, LDL cholesterol, and HDL cholesterol on risk: 3510 cases of acute myocardial infarction and 9805 controls
,
2009,
European heart journal.
[6]
M. Pencina,et al.
Clinical utility of different lipid measures for prediction of coronary heart disease in men and women.
,
2007,
JAMA.
[7]
J. Danesh,et al.
EPIC-Heart: The cardiovascular component of a prospective study of nutritional, lifestyle and biological factors in 520,000 middle-aged participants from 10 European countries
,
2007,
European Journal of Epidemiology.
[8]
G. Dagenais,et al.
Apolipoprotein-B, low-density lipoprotein cholesterol, and the long-term risk of coronary heart disease in men.
,
2006,
The American journal of cardiology.
[9]
A. French.
Reliability of Anergy Skin Testing in Persons with HIV Infection
,
1996
.
[10]
C. Salveson,et al.
Two-stage tuberculin skin testing in individuals with human immunodeficiency virus infection
,
1995
.
[11]
D. Nash,et al.
Anergy in active pulmonary tuberculosis. A comparison between positive and negative reactors and an evaluation of 5 TU and 250 TU skin test doses.
,
1980,
Chest.